{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:12:33Z","timestamp":1778551953535,"version":"3.51.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00228-026-04053-3","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:38:16Z","timestamp":1776213496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory and safety challenges of biosimilars: insights from developed and emerging economies"],"prefix":"10.1007","volume":"82","author":[{"given":"Prerna","family":"Haritwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Lohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4053_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BS.S16120","volume":"1","author":"B Sekhon","year":"2011","unstructured":"Sekhon B, Saluja V (2011) Biosimilars: an overview. Biosimilars 1:1\u201311. https:\/\/doi.org\/10.2147\/BS.S16120","journal-title":"Biosimilars"},{"issue":"4","key":"4053_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/S40138-013-0023-5","volume":"1","author":"K Sylvester","year":"2013","unstructured":"Sylvester K, Rocchio M, Beik N, Fanikos J (2013) Biosimilars: an emerging category of biologic drugs for emergency medicine practitioners. Curr Emerg Hosp Med Rep 1(4):226\u2013235. https:\/\/doi.org\/10.1007\/S40138-013-0023-5","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"4053_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC (2019) Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol 10:279. https:\/\/doi.org\/10.3389\/fphar.2019.00279","journal-title":"Front Pharmacol"},{"issue":"1","key":"4053_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3892\/ol.2019.11105","volume":"19","author":"S Konstantinidou","year":"2020","unstructured":"Konstantinidou S, Papaspiliou A, Kokkotou E (2020) Current and future roles of biosimilars in oncology practice. Oncol Lett 19(1):45\u201351. https:\/\/doi.org\/10.3892\/ol.2019.11105","journal-title":"Oncol Lett"},{"key":"4053_CR5","unstructured":"Biosimilars Market Size, Trends, Growth & Share Analysis 2025\u20132030. https:\/\/www.mordorintelligence.com\/industry-reports\/global-biosimilars-market-industry. Accessed 13 Jan 2026"},{"key":"4053_CR6","doi-asserted-by":"publisher","unstructured":"Kuribayashi R, Hariu A, Saino Y, Shinohara K Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2025 Feb 14:1\u20139. https:\/\/doi.org\/10.1007\/s00210-025-03874-w","DOI":"10.1007\/s00210-025-03874-w"},{"key":"4053_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4161\/mabs.3.2.15005","volume":"3","author":"M McCamish","year":"2011","unstructured":"McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. InMAbs 3:209\u2013217. https:\/\/doi.org\/10.4161\/mabs.3.2.15005","journal-title":"InMAbs"},{"key":"4053_CR8","unstructured":"Biosimilars (2026) expanding access to essential biologic therapies. https:\/\/www.who.int\/news\/item\/13-02-2025-biosimilars--expanding-access-to-essential-biologic-therapies. Accessed 13 Jan"},{"issue":"1","key":"4053_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/JPBS.JPBS_167_18","volume":"11","author":"BR Meher","year":"2019","unstructured":"Meher BR, Balan S, Mohanty RR, Jena M, Das S (2019) Biosimilars in India; current status and future perspectives. J Pharm Bioallied Sci 11(1):12\u201315. https:\/\/doi.org\/10.4103\/JPBS.JPBS_167_18","journal-title":"J Pharm Bioallied Sci"},{"key":"4053_CR10","doi-asserted-by":"publisher","first-page":"726660","DOI":"10.3389\/FMED.2021.726660\/BIBTEX","volume":"8","author":"H Rahalkar","year":"2021","unstructured":"Rahalkar H, Sheppard A, Santos GM, Dasgupta C, Perez-Tapia SM, Lopez-Morales CA, Salek S (2021) Current regulatory requirements for biosimilars in six member countries of BRICS-TM: challenges and opportunities. Front Med 8:726660. https:\/\/doi.org\/10.3389\/FMED.2021.726660\/BIBTEX","journal-title":"Front Med"},{"key":"4053_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CCID.S91691","volume":"17","author":"MG Eleryan","year":"2016","unstructured":"Eleryan MG, Akhiyat S, Rengifo-Pardo M, Ehrlich A (2016) Biosimilars: potential implications for clinicians. Clin Cosmet Invest Dermatology 17:135\u2013142. https:\/\/doi.org\/10.2147\/CCID.S91691","journal-title":"Clin Cosmet Invest Dermatology"},{"key":"4053_CR12","unstructured":"Biosimilars Info Sheet Level (2026) 1: Foundational Concepts Generics and Biosimilars. https:\/\/www.fda.gov\/media\/154912\/download. Accessed 24 Feb"},{"issue":"26","key":"4053_CR13","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/BLOOD-2012-04-425744","volume":"120","author":"M Weise","year":"2012","unstructured":"Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A (2012) Biosimilars: what clinicians should know. Blood J Am Soc Hematol 120(26):5111\u20135117. https:\/\/doi.org\/10.1182\/BLOOD-2012-04-425744","journal-title":"Blood J Am Soc Hematol"},{"key":"4053_CR14","doi-asserted-by":"publisher","unstructured":"Ahmad AS, Olech E, McClellan JE, Kirchhoff CF (2016) Development of biosimilars. In Seminars in arthritis and rheumatism. ; 45:S11-S18. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2016.01.002","DOI":"10.1016\/J.SEMARTHRIT.2016.01.002"},{"key":"4053_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/S10295-019-02216-Z","volume":"46","author":"FK Agbogbo","year":"2019","unstructured":"Agbogbo FK, Ecker DM, Farrand A, Han K, Khoury A, Martin A, McCool J, Rasche U, Rau TD, Schmidt D, Sha M (2019) Current perspectives on biosimilars. J Ind Microbiol Biotechnol 46:1297\u20131311. https:\/\/doi.org\/10.1007\/S10295-019-02216-Z","journal-title":"J Ind Microbiol Biotechnol"},{"key":"4053_CR16","unstructured":"Biosimilars Basics for Patients FDA (2026) https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilars-basics-patients. Accessed 13 Jan"},{"key":"4053_CR17","unstructured":"Biosimilar medicines (2026) Overview | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview. Accessed 13 Jan"},{"issue":"3","key":"4053_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.14982\/RSMP.5.181","volume":"5","author":"N Matsui","year":"2015","unstructured":"Matsui N, Yaguchi D, Murayama K, Toyoshima S (2015) Current Status and Development Trend of Biosimilars in Japan. Regul Sci Med Prod 5(3):181\u2013194. https:\/\/doi.org\/10.14982\/RSMP.5.181","journal-title":"Regul Sci Med Prod"},{"key":"4053_CR19","unstructured":"Guidelines on Similar Biologics | NFS https:\/\/www.nitiforstates.gov.in\/policy-viewer?id=GNC1614Q000146. Accessed 13 Jan 2026"},{"key":"4053_CR20","unstructured":"ANVISA Approves the Regulation of Biosimilars - Lexology https:\/\/www.lexology.com\/library\/detail.aspx?g=04d97d69-392f-43d3-9fcf-7f725665b6b7. Accessed 24 Feb 2026"},{"key":"4053_CR21","unstructured":"REGISTRATION OF MEDICINES BIOSIMILARS AUG-14 (2026) http:\/\/www.sahpra.org.za. Accessed 13 Jan"},{"issue":"5","key":"4053_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/CPT.3180","volume":"115","author":"C Fernandez-Mendivil","year":"2024","unstructured":"Fernandez-Mendivil C, Kinsella NM, Ebbers HC (2024) A retrospective analysis of the potential impact of differences in aggregates on clinical immunogenicity of biosimilars and their reference products. Clin Pharmacol Ther 115(5):1122\u20131131. https:\/\/doi.org\/10.1002\/CPT.3180","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4053_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4155\/bio.14.311","volume":"7","author":"PM Liu","year":"2015","unstructured":"Liu PM, Zou L, Sadhu C, Shen WD, Nock S (2015) Comparative immunogenicity assessment: a critical consideration for biosimilar development. Bioanalysis 7(3):373\u2013381. https:\/\/doi.org\/10.4155\/bio.14.311","journal-title":"Bioanalysis"},{"issue":"4","key":"4053_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I (2020) The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther 108(4):734\u2013755. https:\/\/doi.org\/10.1002\/cpt.1836","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4053_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/S40259-016-0174-5","volume":"30","author":"C Pineda","year":"2016","unstructured":"Pineda C, Casta\u00f1eda Hern\u00e1ndez G, Jacobs IA, Alvarez DF, Carini C (2016) Assessing the immunogenicity of biopharmaceuticals. BioDrugs 30(3):195\u2013206. https:\/\/doi.org\/10.1007\/S40259-016-0174-5","journal-title":"BioDrugs"},{"key":"4053_CR26","doi-asserted-by":"publisher","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies. 2019;;8(1):21 https:\/\/doi.org\/10.3390\/ANTIB8010021","DOI":"10.3390\/ANTIB8010021"},{"issue":"6","key":"4053_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/PH18060908","volume":"17","author":"TG Bas","year":"2025","unstructured":"Bas TG (2025) Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges. Pharmaceuticals 17(6):908. https:\/\/doi.org\/10.3390\/PH18060908","journal-title":"Pharmaceuticals"},{"key":"4053_CR28","doi-asserted-by":"publisher","unstructured":"He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduction and Targeted Therapy. 2024;;9(1):194. https:\/\/doi.org\/10.1038\/s41392-024-01886-1","DOI":"10.1038\/s41392-024-01886-1"},{"key":"4053_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/fon-2018-0553","volume":"15","author":"T Schreitm\u00fcller","year":"2018","unstructured":"Schreitm\u00fcller T, Barton B, Zharkov A, Bakalos G (2018) Comparative Immunogenicity Assessment of Biosimilars. Future Oncol 15:319\u2013329. https:\/\/doi.org\/10.2217\/fon-2018-0553","journal-title":"Future Oncol"},{"issue":"1","key":"4053_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.22270\/ijdra.v12i1.655","volume":"12","author":"N Patel","year":"2024","unstructured":"Patel N, Prajapati H, Joshi N, Movaliya V, Kanaki N, Deshpande S, Zaveri M (2024) Regulatory requirements for approval and registration procedure of biosimilar in US and European Union (EU). Int J Drug Regul Affairs 12(1):70\u201382","journal-title":"Int J Drug Regul Affairs"},{"issue":"5","key":"4053_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-025-00733-1.1","volume":"39","author":"M Schiestl","year":"2025","unstructured":"Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, Wolff-Holz E (2025) Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. BioDrugs 39(5):769\u2013776. https:\/\/doi.org\/10.1007\/s40259-025-00733-1.1","journal-title":"BioDrugs"},{"issue":"16","key":"4053_CR32","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E (2021) Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs 81(16):1881\u20131896. https:\/\/doi.org\/10.1007\/s40265-021-01601-2","journal-title":"Drugs"},{"issue":"1","key":"4053_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L (2017) Biosimilars in IBD: from theory to practice. Nat Reviews Gastroenterol Hepatol 14(1):22\u201331. https:\/\/doi.org\/10.1038\/nrgastro.2016.155","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"4053_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819852535","volume":"12","author":"JE McClellan","year":"2019","unstructured":"McClellan JE, Conlon HD, Bolt MW, Kalfayan V, Palaparthy R, Rehman MI, Kirchhoff CF (2019) The \u2018totality-of-the-evidence\u2019approach in the development of PF-06438179\/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therapeutic Adv Gastroenterol 12:1\u201313. https:\/\/doi.org\/10.1177\/1756284819852535","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"4053_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/978-3-319-99680-6_21","volume-title":"Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development","author":"P Zhu","year":"2018","unstructured":"Zhu P, Skerjanec A (2018) Extrapolation. Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development. Springer International Publishing, Cham, pp 571\u2013599. doi: https:\/\/doi.org\/10.1007\/978-3-319-99680-6_21."},{"key":"4053_CR36","doi-asserted-by":"publisher","first-page":"917814","DOI":"10.3389\/fphar.2022.917814","volume":"24","author":"E Allocati","year":"2022","unstructured":"Allocati E, Godman B, Gobbi M, Garattini S, Banzi R (2022) Switching among biosimilars: a review of clinical evidence. Front Pharmacol 24:13:917814. https:\/\/doi.org\/10.3389\/fphar.2022.917814","journal-title":"Front Pharmacol"},{"key":"4053_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.17235\/REED.2021.7638\/2020","volume":"113","author":"CI Naval\u00f3n","year":"2021","unstructured":"Naval\u00f3n CI, Candel MG, Valverde IS, de Prado IN, Esp\u00edn RG, Redondo LR, Carles IN, Maite GC, Ignacio SV, de Prado Isabel N, Rosa GE (2021) Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival. Rev Esp Enferm Dig 113:770\u2013775. https:\/\/doi.org\/10.17235\/REED.2021.7638\/2020","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"4053_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00228-018-2542-1","volume":"18","author":"J O\u2019Callaghan","year":"2019","unstructured":"O\u2019Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT (2019) Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol 18(1):1\u20131. https:\/\/doi.org\/10.1007\/S00228-018-2542-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4053_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/CELLS10020441","volume":"19","author":"BJ Peters","year":"2021","unstructured":"Peters BJ, Bhatoe A, Vorselaars AD, Veltkamp M (2021) Switching to an infliximab biosimilar was safe and effective in Dutch sarcoidosis patients. Cells 19(2):441. https:\/\/doi.org\/10.3390\/CELLS10020441","journal-title":"Cells"},{"issue":"3","key":"4053_CR40","doi-asserted-by":"publisher","first-page":"613","DOI":"10.55563\/CLINEXPRHEUMATOL\/BF00J9","volume":"1","author":"R Scrivo","year":"2023","unstructured":"Scrivo R, Castellani C, Mancuso S, Sciarra G, Giardina F, Bevignani G, Ceccarelli F, Spinelli FR, Alessandri C, Di Franco M, Riccieri V (2023) Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol 1(3):613\u2013619. https:\/\/doi.org\/10.55563\/CLINEXPRHEUMATOL\/BF00J9","journal-title":"Clin Exp Rheumatol"},{"key":"4053_CR41","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/J.YRTPH.2019.104525","volume":"1110","author":"AS Rathore","year":"2020","unstructured":"Rathore AS, Bhargava A (2020) Biosimilars in developed economies: overview, status, and regulatory considerations. Regul Toxicol Pharmacol 1110:104525. https:\/\/doi.org\/10.1016\/J.YRTPH.2019.104525","journal-title":"Regul Toxicol Pharmacol"},{"issue":"7","key":"4053_CR42","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/14712598.2013.783560","volume":"1","author":"N Casadevall","year":"2013","unstructured":"Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG (2013) Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther 1(7):1039\u20131047. https:\/\/doi.org\/10.1517\/14712598.2013.783560","journal-title":"Expert Opin Biol Ther"},{"key":"4053_CR43","unstructured":"Inflectra. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra. Accessed 13 Jan"},{"issue":"6","key":"4053_CR44","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/J.SEMARTHRIT.2015.04.005","volume":"44","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Smolen J (2015) Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 44(6):S9\u2013S15. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2015.04.005","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"4053_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/17512433.2017.1293522","volume":"3","author":"S Bonovas","year":"2017","unstructured":"Bonovas S, Peyrin-Biroulet L, Danese S (2017) Clinical development of biologicals and biosimilars-safety concerns. Expert Rev Clin Pharmacol 3(6):567\u2013569. https:\/\/doi.org\/10.1080\/17512433.2017.1293522","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"4053_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/PHARMACEUTICS13010048","volume":"31","author":"I Gherghescu","year":"2020","unstructured":"Gherghescu I, Delgado-Charro MB (2020) The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics 31(1):48. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13010048","journal-title":"Pharmaceutics"},{"key":"4053_CR47","unstructured":"FDA exempts biosimilar drug from Clinical Efficacy Studies (2026) Mabion. Available: https:\/\/www.mabion.eu\/science-hub\/science-news\/fda-grants-first-ever-waiver-of-clinical-efficacy-studies-for-monoclonal-antibody-biosimilar\/. Accessed 12 Jan"},{"key":"4053_CR48","unstructured":"Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2026) Updated Recommendations for Assessing the Need for Comparative Efficacy Studies | FDA. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations. Accessed 7 Jan"},{"issue":"4","key":"4053_CR49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/CAM4.258","volume":"3","author":"LH Camacho","year":"2014","unstructured":"Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S (2014) Biosimilars 101: considerations for US oncologists in clinical practice. Cancer Med 3(4):889\u2013899. https:\/\/doi.org\/10.1002\/CAM4.258","journal-title":"Cancer Med"},{"key":"4053_CR50","unstructured":"Fda C, Purdie, Florine P (2015) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry, Available: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. Accessed 13 Jan 2026"},{"key":"4053_CR51","doi-asserted-by":"crossref","unstructured":"Jordan JB, Christl L (2020) FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars? Expert Opinion on Drug Safety. ; 3;19(3):229\u2009\u2013\u200932. doi: 10.1080\/14740338.2020.1733966;ISSUE:ISSUE:DOI","DOI":"10.1080\/14740338.2020.1733966"},{"key":"4053_CR52","doi-asserted-by":"publisher","unstructured":"Felix T, Patel B, Bradbury BD, Grampp G (2018) Pharmacovigilance of biosimilars: global experience and perspective. Biosimilars: Regulatory, clinical, and biopharmaceutical development. 14:631\u2013652. https:\/\/doi.org\/10.1007\/978-3-319-99680-6_23","DOI":"10.1007\/978-3-319-99680-6_23"},{"key":"4053_CR53","unstructured":"Food U, Administration D (2026) Biosimilar Product Regulatory Review and Approval What is the approval process for biosimilar products? Available: www.fda.gov. Accessed 13 Jan"},{"key":"4053_CR54","unstructured":"Regulation\u2009\u2013\u20091235\/ 2010 - EN - EUR-Lex. Available: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32010R1235. Accessed 13 Jan 2026"},{"issue":"7","key":"4053_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14712598.2017.1330409","volume":"3","author":"MD Portela","year":"2017","unstructured":"Portela MD, Sinogas C, Albuquerque de Almeida F, Baptista-Leite R, Castro-Caldas A (2017) Biologicals and biosimilars: safety issues in Europe. Expert Opin Biol Ther 3(7):871\u2013877. https:\/\/doi.org\/10.1080\/14712598.2017.1330409","journal-title":"Expert Opin Biol Ther"},{"key":"4053_CR56","unstructured":"Streamlining development and assessment of biosimilar medicines | European Medicines Agency (EMA) (2026) Available: https:\/\/www.ema.europa.eu\/en\/news\/streamlining-development-assessment-biosimilar-medicines. Accessed 7 Jan"},{"issue":"1","key":"4053_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1057\/jgm.2010","volume":"8","author":"S Ruiz","year":"2011","unstructured":"Ruiz S, Calvo G (2011) Similar biological medicinal products: lessons learned and challenges ahead. J Generic Med 8(1):4\u201313. https:\/\/doi.org\/10.1057\/jgm.2010","journal-title":"J Generic Med"},{"key":"4053_CR58","unstructured":"Europe and FDA guidance on biosimilar interchangeability | Biosimilars (2026) Available: https:\/\/www.biosimilars.stada\/blog\/posts\/2020\/august\/europe-and-fda-guidance-on-biosimilar-interchangeability. Accessed 13 Jan"},{"issue":"5","key":"4053_CR59","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.clinthera.2016.02.023","volume":"1","author":"M Khraishi","year":"2016","unstructured":"Khraishi M, Stead D, Lukas M, Scotte F, Schmid H (2016) Biosimilars: a multidisciplinary perspective. Clin Ther 1(5):1238\u20131249. https:\/\/doi.org\/10.1016\/j.clinthera.2016.02.023","journal-title":"Clin Ther"},{"issue":"1","key":"4053_CR60","doi-asserted-by":"publisher","first-page":"2529183","DOI":"10.1080\/13102818.2025.2529183","volume":"39","author":"V Kopanarov","year":"2025","unstructured":"Kopanarov V, Benisheva T, Naydenova R, Gergova V, Dimitrov D, Sidjimova D, Mateev H (2025) Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept). Biotechnol Biotechnol Equip 39(1):2529183. https:\/\/doi.org\/10.1080\/13102818.2025.2529183","journal-title":"Biotechnol Biotechnol Equip"},{"key":"4053_CR61","doi-asserted-by":"publisher","unstructured":"Kohl S (Oct. 2022) EMA\/HMA joint statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. Eur J Hosp Pharm 29(6):363. https:\/\/doi.org\/10.1136\/EJHPHARM-2022-003571","DOI":"10.1136\/EJHPHARM-2022-003571"},{"key":"4053_CR62","unstructured":"Naohiro O (2024) Regulatory and Scientific Considerations for Biosimilars in Japan Principal Reviewer Office of Cellular and Tissue-based Products. PMDA"},{"issue":"3","key":"4053_CR63","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/J.XPHS.2017.10.040","volume":"107","author":"R Kuribayashi","year":"2018","unstructured":"Kuribayashi R, Sawanobori K (2018) Current Japanese regulatory systems for generics and biosimilars. J Pharm Sci 107(3):785\u2013787. https:\/\/doi.org\/10.1016\/J.XPHS.2017.10.040","journal-title":"J Pharm Sci"},{"issue":"3","key":"4053_CR64","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1470-2045(21)00029-2","volume":"22","author":"S Nagai","year":"2021","unstructured":"Nagai S (2021) Current situation of oncology biosimilars in Japan. Lancet Oncol 22(3):e82. https:\/\/doi.org\/10.1016\/S1470-2045(21)00029-2","journal-title":"Lancet Oncol"},{"key":"4053_CR65","doi-asserted-by":"publisher","unstructured":"Kuribayashi R, Hariu A, Nakano A, Kishioka Y (2024) Pharm Med 38(3):225\u2013239. https:\/\/doi.org\/10.1007\/S40290-024-00525-Y. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments","DOI":"10.1007\/S40290-024-00525-Y"},{"issue":"7","key":"4053_CR66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/14712598.2024.2377300","volume":"2","author":"R Kuribayashi","year":"2024","unstructured":"Kuribayashi R, Goto K, Hariu A, Kishioka Y (2024) Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan. Expert Opin Biol Ther 2(7):637\u2013645. https:\/\/doi.org\/10.1080\/14712598.2024.2377300","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"4053_CR67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/S40259-023-00605-6","volume":"1","author":"R Kuribayashi","year":"2023","unstructured":"Kuribayashi R, Nakano A, Hariu A, Kishioka Y, Honda F (2023) Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009\u20132022. BioDrugs 1(4):443\u2013451. https:\/\/doi.org\/10.1007\/S40259-023-00605-6","journal-title":"BioDrugs"},{"issue":"6","key":"4053_CR68","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/S40259-019-00377-Y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, Weise M (2019) Evolution of the EU biosimilar framework: past and future. BioDrugs 33(6):621\u2013634. https:\/\/doi.org\/10.1007\/S40259-019-00377-Y","journal-title":"BioDrugs"},{"key":"4053_CR69","unstructured":"Search | European Medicines Agency (EMA) Available: https:\/\/www.ema.europa.eu\/en\/search?f%5B0%5D=ema_med_status%3A100108&f%5B1%5D=ema_medicine_bundle%3Aema_medicine&f%5B2%5D=ema_medicine_type_fields%3Afield_ema_biosimilar&f%5B3%5D=ema_search_categories%3A83&landing_from=73303. Accessed 13 Jan 2026"},{"key":"4053_CR70","unstructured":"PMDA Approved Biosimilars (2025) 2025. https:\/\/www.pmda.go.jp\/files\/000278462.pdf. Accessed 13 Jan 2026"},{"issue":"1","key":"4053_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2167-7689.1000165","volume":"5","author":"P Rushvi","year":"2016","unstructured":"Rushvi P, Charmy K, Nirav C, Narendra C (2016) Biosimilars: an emerging market opportunity in India. Pharm Regul Affairs 5(1):1\u20137. https:\/\/doi.org\/10.4172\/2167-7689.1000165","journal-title":"Pharm Regul Affairs"},{"issue":"1104","key":"4053_CR72","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/POSTGRADMEDJ-2017-134806","volume":"93","author":"R Jois","year":"2017","unstructured":"Jois R (2017) The brave new world of biosimilars (\u2018similar biologics\u2019) in India. Postgrad Med J 93(1104):577\u2013579. https:\/\/doi.org\/10.1136\/POSTGRADMEDJ-2017-134806","journal-title":"Postgrad Med J"},{"key":"4053_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.18433\/JPPS32433","volume":"25","author":"Z Iqbal","year":"2022","unstructured":"Iqbal Z, Sadaf S, Biosimilars (2022) A comparative study of regulatory, safety and pharmacovigilance monograph in the developed and developing economies. J Pharm Pharm Sci 25:149\u2013182. https:\/\/doi.org\/10.18433\/JPPS32433","journal-title":"J Pharm Pharm Sci"},{"key":"4053_CR74","unstructured":"Revised Guidelines on Similar Biologics-Regulatory. Available: https:\/\/medicaldialogues.in\/pdf_upload\/draft-guidelines-on-similar-biologics-2025-285933.pdf. Accessed 13 Jan 2026"},{"key":"4053_CR75","doi-asserted-by":"publisher","unstructured":"Shekhar R, Muralidharan P, Hallur N, Puranik SB. Regulatory outlook from concept to commercialization of Biosimilars in Brazil market (2020) Asian J Pharm Res Dev 8(2):67\u201374. https:\/\/doi.org\/10.22270\/ajprd.v8i2.672","DOI":"10.22270\/ajprd.v8i2.672"},{"key":"4053_CR76","unstructured":"Navigating RDC 875\/2024: Maven\u2019s Support for Biosimilars in Brazil. https:\/\/www.mavenrs.com\/Navigating-the-Brazilian-Market-with-RDC-8752024-How-Maven-Supports-Your-Biosimilars-Journey. Accessed 24 Feb 2026"},{"key":"4053_CR77","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.22270\/jmpas.V11I1.2158","volume":"11","author":"N Pasam","year":"2022","unstructured":"Pasam N, Kamaraj R (2022) Regulation & registration of drugs and biologics in Brazil. J Med Pharm Allied Sci 11:4332\u20134339. https:\/\/doi.org\/10.22270\/jmpas.V11I1.2158","journal-title":"J Med Pharm Allied Sci"},{"issue":"12","key":"4053_CR78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1759720X188096","volume":"10","author":"MR de Assis","year":"2018","unstructured":"de Assis MR, Pinto V (2018) Strengths and weaknesses of the Brazilian regulation on biosimilars: a critical view of the regulatory requirements for biosimilars in Brazil. Therapeutic Adv Musculoskelet Disease 10(12):253\u2013259. https:\/\/doi.org\/10.1177\/1759720X188096","journal-title":"Therapeutic Adv Musculoskelet Disease"},{"key":"4053_CR79","unstructured":"Naidoo M, Thibane T, Tunyiswa P (2024) Competitive Landscape of Biosimilars in South Africa. Working paper CC2024\/02. Available: https:\/\/www.compcom.co.za\/wp-content\/uploads\/2024\/10\/CC202402-Melissa-Naidoo-Tankiso-Thibane-and-Phakamani-Tunyiswa.-Competitive-Landscape-of-Biosimilars-in-South-Africa.pdf. Accessed 15 Jan"},{"key":"4053_CR80","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/S12889-023-15021-2","volume":"23","author":"N Mpanza","year":"2023","unstructured":"Mpanza N (2023) Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries. BMC Public Health 23:192. https:\/\/doi.org\/10.1186\/S12889-023-15021-2","journal-title":"BMC Public Health"},{"key":"4053_CR81","unstructured":"Quality BM (2026) Non-clinical and Clinical Requirements - SAHPRA. Available: https:\/\/www.sahpra.org.za\/document\/biosimilar-medicine-quality-non-clinical-and-clinical-requirements\/. Accessed 13 Jan"},{"key":"4053_CR82","unstructured":"Guidelines. Available (2026) https:\/\/www.sahpra.org.za\/guidelines\/. Accessed 13 Jan"},{"key":"4053_CR83","unstructured":"Agency EM (2014) Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, Available: www.ema.europa.eu\/contact. Accessed 13 Jan 2026"},{"issue":"3","key":"4053_CR84","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1741134312459187","volume":"9","author":"S Vashisth","year":"2012","unstructured":"Vashisth S, Singh G, Nanda A (2012) A comparative study of regulatory trends of pharmaceuticals in Brazil, Russia, India and China (BRIC) countries. J Generic Med 9(3):128\u2013143. https:\/\/doi.org\/10.1177\/1741134312459187","journal-title":"J Generic Med"},{"key":"4053_CR85","unstructured":"Guideline for Ensuring Quality (2026) Safety, and Efficacy of Biosimilars. https:\/\/www.pmda.go.jp\/files\/000267479.pdf. Accessed 16 Jan"},{"key":"4053_CR86","unstructured":"Questions and Answers on Biosimilar Development and the BPCI Act (2026) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-biosimilar-development-and-bpci-act. Accessed 26 Mar"},{"key":"4053_CR87","unstructured":"Multidisciplinary: biosimilar | European Medicines Agency (EMA). Available (2026) https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-biosimilar. Accessed 13 Jan"},{"key":"4053_CR88","unstructured":"Nomenclature of biologicals and biosimilars in Brazil (2026) Available: https:\/\/www.gabionline.net\/policies-legislation\/nomenclature-of-biologicals-and-biosimilars-in-brazil. Accessed 13 Jan"},{"issue":"2","key":"4053_CR89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/S43441-024-00740-4","volume":"59","author":"TM Kirchlechner","year":"2025","unstructured":"Kirchlechner TM, Cohen HP (2025) Global harmonization of biosimilar development by overcoming existing differences in regional regulatory requirements-outcomes of a descriptive review. Therapeutic Innov Regul Sci 59(2):245\u2013255. https:\/\/doi.org\/10.1007\/S43441-024-00740-4","journal-title":"Therapeutic Innov Regul Sci"},{"issue":"10","key":"4053_CR90","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1634\/THEONCOLOGIST.2017-0671","volume":"23","author":"E Cazap","year":"2018","unstructured":"Cazap E, Jacobs I, McBride A, Popovian R, Sikora K (2018) Global acceptance of biosimilars: importance of regulatory consistency, education, and trust. Oncologist 23(10):1188\u20131198. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2017-0671","journal-title":"Oncologist"},{"issue":"10","key":"4053_CR91","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1016\/J.SAPHARM.2022.03.009","volume":"18","author":"C Gasteiger","year":"2022","unstructured":"Gasteiger C, Petrie KJ (2022) Moving forward: implementing health psychology research to improve patient acceptance of biosimilars. Res Social Administrative Pharm 18(10):3860\u20133863. https:\/\/doi.org\/10.1016\/J.SAPHARM.2022.03.009","journal-title":"Res Social Administrative Pharm"},{"issue":"5","key":"4053_CR92","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/J.JVAL.2025.02.008","volume":"28","author":"M Jofre-Bonet","year":"2025","unstructured":"Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD (2025) The price effects of biosimilars in the united states. Value Health 28(5):742\u2013750. https:\/\/doi.org\/10.1016\/J.JVAL.2025.02.008","journal-title":"Value Health"},{"issue":"6","key":"4053_CR93","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/S40259-023-00620-7","volume":"37","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang Z, Wang X, Yu H, Sun J, Wu et al (2023) BioDrugs 37(6):829\u2013841. https:\/\/doi.org\/10.1007\/S40259-023-00620-7","journal-title":"BioDrugs"},{"key":"4053_CR94","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","volume":"26","author":"I Jacobs","year":"2016","unstructured":"Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG (2016) Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence 26:937\u2013948. https:\/\/doi.org\/10.2147\/PPA.S104891","journal-title":"Patient Prefer Adherence"},{"key":"4053_CR95","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Final Concept Paper M18 (2026) Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf. Accessed 7 Jan"},{"key":"4053_CR96","unstructured":"Guidelines on evaluation of biosimilars (2026) https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-evaluation-of-biosimilars. Accessed 7 Jan"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04053-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:46:43Z","timestamp":1778550403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4053"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04053-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}